Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, Montreal, Canada, June 17-22, 2017.
Patricia Novo, MPA, MPH (NYU School of Medicine, GNY Node), Edward V. Nunes, MD (Columbia University, GNY Node), Jennifer Scodes, MD (Columbia University, GNY Node), Martina Pavlicova, PhD (Columbia University, GNY Node), Joshua D. Lee, MD (NYU School of Medicine), Jeanine May, PhD (Emmes Corporation), Dagmar Salazar, MS (Emmes Corporation), Dikla Shmueli-Blumberg, PhD (Emmes Corporation), John Rotrosen, MD (NYU School of Medicine).
This poster describes the population enrolled in the "Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)" CTN study (CTN-0051), a comparative effectiveness trial assessing extended release injectable naltrexone (XR-NTX) versus buprenorphine-naloxone (BUP-NX) as pharmacotherapeutic aids to recovery amongst treatment-seeking participants with opioiud use disorder. Baseline data about participants collected includes demographics, opioid use, and clinical characteristics, such as depression, hepatitis B and C status, and pain. Secondary aims are to examine subsets of the population, such as those with high levels of opioid use prior to the start of treatment. (Poster, PDF, English, 2018)
Keywords: Buprenorphine/Naloxone | Naltrexone | Opioid dependence | Pharmacological therapy | College on Problems of Drug Dependence (CPDD) annual meeting, 2017
Document No: 1320.
Submitted by Patricia Novo, GNY Node, 7/24/2018.